Literature DB >> 17107048

Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety.

Howard Bregman1, Eric Meggers.   

Abstract

Cyclopentadienyl half-sandwich ruthenium complexes have been demonstrated to be promising scaffolds as protein kinase inhibitors. In order to rapidly identify derivatives which display modified pharmacological properties, we developed the synthesis of an organoruthenium compound bearing an N-succinimidyl ester at the cyclopentadienyl moiety. The quenching of this activated ester with a library of primary amines, followed by testing of the resulting amide library, led to the identification of organometallic Pim-1 and GSK-3 inhibitors with improved potencies and kinase selectivities. [structure: see text].

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107048     DOI: 10.1021/ol0620646

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  16 in total

1.  Enzyme microarrays assembled by acoustic dispensing technology.

Authors:  E Y Wong; S L Diamond
Journal:  Anal Biochem       Date:  2008-06-20       Impact factor: 3.365

Review 2.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

Review 3.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 4.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

5.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Authors:  Zuping Xia; Christian Knaak; Jian Ma; Zanna M Beharry; Campbell McInnes; Wenxue Wang; Andrew S Kraft; Charles D Smith
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

6.  From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors.

Authors:  Nicholas Pagano; Eric Y Wong; Tom Breiding; Haidong Liu; Alexander Wilbuer; Howard Bregman; Qi Shen; Scott L Diamond; Eric Meggers
Journal:  J Org Chem       Date:  2009-12-04       Impact factor: 4.354

7.  Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor.

Authors:  Ruchi Anand; Jasna Maksimoska; Nicholas Pagano; Eric Y Wong; Phyllis A Gimotty; Scott L Diamond; Eric Meggers; Ronen Marmorstein
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

8.  Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

Authors:  Peng Xie; Douglas S Williams; G Ekin Atilla-Gokcumen; Leslie Milk; Min Xiao; Keiran S M Smalley; Meenhard Herlyn; Eric Meggers; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2008-05-16       Impact factor: 5.100

9.  A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.

Authors:  Yingting Liu; Neeraj J Agrawal; Ravi Radhakrishnan
Journal:  J Mol Model       Date:  2012-08-29       Impact factor: 1.810

Review 10.  Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.

Authors:  Sébastien Deslandes; Stefan Chassaing; Evelyne Delfourne
Journal:  Mar Drugs       Date:  2009-12-01       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.